Skip to main content
v2026.11,986 entries · CC-BY 4.0
LAC HealthSponsored

Shop medical supplies

  • FDA registered
  • ISO 13485
  • BBB Accredited A+

Shop at LAC Health

Editorial · CASRAI · Clinical research and clinical trials

Phase 3b REDEFINE 9 Trial: Lower-Dose CagriSema Cuts Weight by 21% Over 68 Weeks

Novo Nordisk’s Phase 3b REDEFINE 9 trial shows lower-dose CagriSema achieved up to 21% weight reduction over 68 weeks in adults without type 2 diabetes.

Medically reviewed byDr. Diana Nieves Castro, MD
Published 20 Nov 2026· Last updated 20 Nov 2026· 7 minute read
Clinical pathology and medical laboratory environment configured for blood sample analysis and specimen processing
Photo: Goleisureintl / Wikimedia Commons, CC BY 4.0 (cropped). Source · Licence

Primary results from the Phase 3b REDEFINE 9 trial published on 14 November 2026 in The Lancet Diabetes and Endocrinology show that lower maintenance doses of CagriSema achieved a 21.0% mean weight reduction over 68 weeks in adults with overweight or obesity without diabetes. Presented at ObesityWeek 2026 in Washington, D.C., the findings demonstrate that sub-maximal dose tiers yield clinically meaningful weight loss while preserving therapeutic flexibility.

What happened

On 14 November 2026, primary results from the Phase 3b REDEFINE 9 randomized controlled trial were presented at the ObesityWeek 2026 annual meeting in Washington, D.C., and simultaneously published in The Lancet Diabetes and Endocrinology. The study, led by Dr. Sean Wharton of the Wharton Medical Clinic and the University of Toronto alongside international academic co-investigators, evaluated sub-maximal maintenance doses of CagriSema in adults with overweight or obesity who do not have type 2 diabetes.

CagriSema is an investigational once-weekly subcutaneous combination therapy developed by Novo Nordisk that combines cagrilintide, a long-acting amylin analogue, with semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. While the ongoing Phase 3 REDEFINE clinical development program has predominantly focused on the maximum planned maintenance dose of 2.4 mg cagrilintide and 2.4 mg semaglutide, REDEFINE 9 is the first Phase 3 trial to assess lower maintenance dose tiers: 1.0 mg/1.0 mg and 1.7 mg/1.7 mg.

Over 68 weeks of treatment, participants receiving the lower doses achieved substantial weight reductions. Under the primary efficacy estimand—which evaluates outcomes assuming full treatment adherence without rescue interventions—participants taking CagriSema 1.0 mg/1.0 mg achieved an estimated mean weight reduction of 21.0%, while those taking CagriSema 1.7 mg/1.7 mg achieved an estimated mean reduction of 20.7%. The pooled placebo group recorded a 2.0% mean weight reduction, yielding estimated treatment differences of 19.0 and 18.8 percentage points versus placebo (p < 0.0001 for both comparisons).

Key details

The REDEFINE 9 trial, registered under ClinicalTrials.gov identifier NCT06388187, was conducted across international clinical trial sites in the United States, Canada, the United Kingdom, France, and Germany. The study utilized double-blind trial masking within dose levels to maintain objective evaluation across the 68-week treatment window.

The trial enrolled 309 adults aged 18 years or older with either a body mass index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater accompanied by at least one weight-related complication such as hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. Individuals with glycated hemoglobin (HbA1c) of 6.5% or higher or a diagnosis of diabetes were excluded. At baseline, participants had a mean age of 48.0 years, a mean body weight of 107.4 kg, a mean BMI of 39.1 kg/m², and 77% were female.

Participants were randomized in a 2:1:2:1 ratio into four parallel cohorts: CagriSema 1.7 mg/1.7 mg (n=104), matching placebo for 1.7 mg, CagriSema 1.0 mg/1.0 mg (n=103), and matching placebo for 1.0 mg. Placebo groups were pooled for primary analysis (n=102). In addition to pharmacotherapy, all participants received standardized nutritional and physical activity counseling.

Trial statisticians reported both treatment-regimen and efficacy estimand analyses. Under the treatment-regimen estimand, which reflects outcomes irrespective of treatment discontinuation, mean weight loss was 18.6% for 1.0 mg/1.0 mg and 19.4% for 1.7 mg/1.7 mg, compared with 4.6% for placebo.

Outcome Measure CagriSema 1.0 mg / 1.0 mg (n=103) CagriSema 1.7 mg / 1.7 mg (n=104) Pooled Placebo (n=102)
Mean Weight Loss (Efficacy Estimand) 21.0% 20.7% 2.0%
Mean Weight Loss (Treatment-Regimen Estimand) 18.6% 19.4% 4.6%
Participants Achieving ≥5% Weight Loss 96.3% 95.1% 33.4%
Participants Achieving ≥15% Weight Loss 70.6% 69.9% 8.8%
Participants Achieving ≥20% Weight Loss 53.4% 51.5% 4.9%
Mean Waist Circumference Reduction 17.5 cm 17.2 cm 3.6 cm
Adverse Event Discontinuation Rate 4.9% 2.9% 4.9%

Secondary endpoints demonstrated significant improvements across cardiometabolic risk markers. Waist circumference decreased by an average of 17.5 cm in the 1.0 mg group and 17.2 cm in the 1.7 mg group, compared with 3.6 cm for placebo. More than 95% of participants in both CagriSema arms attained at least 5% weight loss, approximately 70% reached 15% or greater, and more than half achieved at least 20% total body weight reduction.

The safety profile aligned with incretin and amylin pharmacology. The most common adverse events were gastrointestinal (nausea, diarrhoea, vomiting, and constipation), predominantly mild to moderate and concentrated during titration. Adverse event discontinuations occurred in 4.9% of the 1.0 mg arm, 2.9% of the 1.7 arm, and 4.9% of the placebo group.

Background and context

Incretin-based therapies have reshaped obesity medicine over the past five years. Single-agent semaglutide 2.4 mg (Wegovy) demonstrated approximately 15% to 17% mean weight loss in Phase 3 trials, while dual GLP-1/GIP agonists like tirzepatide reached 20% to 22% at their highest maintenance tiers. However, gastrointestinal adverse events often limit patient tolerability during upward titration, highlighting a need for diverse mechanistic approaches.

CagriSema combines two complementary neuroendocrine pathways. Cagrilintide is a lipidated amylin analogue that acts on calcitonin and amylin receptors in the area postrema and hypothalamus, delaying gastric emptying and increasing satiation. Semaglutide acts via GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon release, and reduce hunger. Preclinical studies demonstrated that activating both pathways produces synergistic metabolic effects.

Novo Nordisk initiated the REDEFINE program to validate this dual-hormone approach across varied clinical cohorts. While earlier trials focused on the maximal 2.4 mg/2.4 mg dose, establishing efficacy at lower dose levels within Phase 3 clinical trial frameworks provides critical evidence regarding whether sub-maximal maintenance doses can achieve target clinical outcomes.

Reaction

Endocrinologists and obesity researchers attending ObesityWeek 2026 highlighted the striking observation that weight loss was virtually identical between the 1.0 mg/1.0 mg (21.0%) and 1.7 mg/1.7 mg (20.7%) dose tiers. This finding suggests a plateau in the weight-loss dose-response relationship above 1.0 mg for this formulation.

Lead investigator Dr. Sean Wharton emphasized that demonstrating substantial efficacy at lower doses provides valuable clinical flexibility. In routine practice, patients who encounter persistent gastrointestinal discomfort at higher maintenance steps often discontinue treatment; proving that 1.0 mg/1.0 mg provides 21% weight reduction ensures that dose reductions do not compromise clinical benefit.

Industry analysts reporting in BioSpace and Clinical Trial Vanguard noted that achieving over 20% weight reduction with lower doses and low discontinuation rates strengthens CagriSema’s competitive profile against dual and triple incretin agonists entering late-phase evaluation.

What it means for researchers, universities and research offices

The REDEFINE 9 results offer actionable operational insights for academic clinical investigators and university research administrative offices involved in metabolic clinical trials.

For trial design teams and principal investigators, the study underscores the value of testing multiple maintenance dose levels within late-phase protocols. Rather than assuming that maximum tolerated doses are necessary for peak efficacy, protocols that incorporate intermediate tiers can identify therapeutic plateaus and improve long-term participant retention.

For university clinical trials offices and research pharmacies, multi-tier investigational regimens demand strict adherence to investigational medicinal product (IMP) accountability, temperature logging, and precise dispensation tracking during protocol-mandated titration steps.

Institutional Review Boards (IRBs) and Data Safety Monitoring Boards (DSMBs) must assess the cumulative tolerability burden of multi-target hormonal therapies, ensuring that safety monitoring specifically tracks gastrointestinal risks and potential overlapping toxicities.

Finally, the trial illustrates the importance of clinical trial transparency. By publishing complete estimand datasets, secondary outcomes, and registry updates concurrently with scientific presentation, the investigators demonstrate best practices for rapid, peer-reviewed clinical data dissemination.

What happens next

CagriSema remains an investigational combination drug that is not yet approved by the US Food and Drug Administration, the European Medicines Agency, or any other regulatory agency for weight management or diabetes care.

Novo Nordisk is advancing the broader REDEFINE development program. Forthcoming readouts include REDEFINE 1 (evaluating the 2.4 mg/2.4 mg maintenance dose in obesity) and REDEFINE 2 (evaluating adults with type 2 diabetes). Furthermore, the long-term REDEFINE 3 cardiovascular outcomes trial continues to evaluate major adverse cardiovascular events in participants with pre-existing cardiovascular conditions.

Data from REDEFINE 9 will be included in planned regulatory submissions following completion of the primary Phase 3 trials, while academic trialists conduct ongoing secondary analyses to evaluate biomarker and metabolic predictors of response.

Sources

Ask CASRAI · free to try

Ask about this story

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →